Nanotechnology platform for cell-based magnetic assays

用于细胞磁性测定的纳米技术平台

• 批准号: 7086794
• 负责人: Mark S. DiIorio
• 金额: $ 12.01万
• 依托单位: MAGNESENSORS, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7086794
• 关键词: biomagnetism measurement; biosensor device; cell surface receptors; cytology; immunologic assay /test; magnetic field; nanotechnology; particle; superconductivity; technology /technique development; temperature

DESCRIPTION (provided by applicant): MagneSensors' program is aimed at developing a nanotechnology platform that uses ultra-sensitive magnetic sensors and magnetic labels to perform powerful new cell assays on live cells. This magnetic detection platform uses high temperature (high-Tc) superconducting quantum interference devices (SQUIDs) to detect the magnetic field generated by biomolecules tagged with magnetic nanoparticles. The Phase I effort is specifically aimed at employing innovative nanotechnology to reduce and control critical dimensions in magnetic sensors and magnetic nanoparticle labels to drive next generation instrumentation and then demonstrating applicability in sensitive cell assays. Phase I uses model systems for proof-of-concept cell assays. Cell assay specific aims include: 1) detection of cell surface receptors (ICAM-1) on 100 adherent live cells (HUVEC), 2) detection of cell surface receptors (Ig) on 10 non-adherent live cells (CRL-1923), and 3) detection of 50 "rare" B cells in a background of 10,000 "normal" T cells. Smaller (10-20 nm) active devices to improve the magnetic sensors, and small (30-80 nm), more uniform, and more powerful magnetic nanoparticles are required to further push the instrument sensitivity towards the ambitious Phase II goals of single cell detection and rare cell detection. The benefits of the new cell assays include: a) the sensitive detection of rare cells within a "normal" cell population (such as fetal cells in maternal blood, metastatic tumor cells, infected host cells), b) ultra-sensitive "mix and measure" assays on cell surface receptors or proteins capable of being performed on a finger stick of blood and no sample preparation. The latter could eventually replace cell culturing for the rapid detection of infections (e.g. sepsis and septic shock) where an immediate answer is needed and delay can prove fatal. This "nanobiotechnology" program will benefit from the close interdisciplinary collaboration of an experienced group of physicists, chemists, and biologists.

描述（由申请人提供）： MagneSensors 的计划旨在开发一个纳米技术平台，该平台使用超灵敏磁传感器和磁性标签对活细胞进行强大的新细胞分析。该磁性检测平台使用高温（高Tc）超导量子干涉装置（SQUID）来检测由磁性纳米颗粒标记的生物分子产生的磁场。 第一阶段的工作具体旨在采用创新的纳米技术来减少和控制磁性传感器和磁性纳米颗粒标签的关键尺寸，以驱动下一代仪器，然后展示其在敏感细胞测定中的适用性。第一阶段使用模型系统进行概念验证细胞测定。细胞测定的具体目标包括：1) 检测 100 个贴壁活细胞 (HUVEC) 上的细胞表面受体 (ICAM-1)，2) 检测 10 个非贴壁活细胞 (CRL-1923) 上的细胞表面受体 (Ig)，以及 3) 在 10,000 个“正常”T 细胞背景中检测 50 个“稀有”B 细胞。 需要更小的（10-20 nm）有源器件来改进磁传感器，以及更小（30-80 nm）、更均匀、更强大的磁性纳米颗粒，以进一步推动仪器灵敏度向单细胞检测和稀有细胞检测的雄心勃勃的第二阶段目标迈进。 新细胞检测的优点包括：a) 灵敏检测“正常”细胞群中的稀有细胞（例如母血中的胎儿细胞、转移性肿瘤细胞、受感染的宿主细胞），b) 对细胞表面受体或蛋白质进行超灵敏“混合和测量”检测，能够在指尖采血上进行，无需样品制备。后者最终可能取代细胞培养来快速检测感染（例如败血症和败血性休克），需要立即得到答案，而延误可能会致命。 这个“纳米生物技术”项目将受益于经验丰富的物理学家、化学家和生物学家团队的密切跨学科合作。